TRIlogy-3
Multiple myeloma
A Phase 2, single-arm, open-label study of ramantamig (JNJ-79635322) in relapsed or refractory MM
Phase
Compound
Ramantamig (JNJ-79635322; BCMA × GPRC5D × CD3 trispecific Ab)
NCT identifier
NCT07266441
Enrollment
N=~157
For more information, including
contact details, please visit
the J&J Clinical Trial Finder
contact details, please visit
the J&J Clinical Trial Finder
Study overview & design
Key eligibility criteria*:
- ≥3 prior lines
- Triple-class exposed (PI, iMiD, anti-CD38 mAb)
Study
design
Primary outcome:
- ORR
Secondary outcomes†:
- ≥VGPR
- ≥CR
- DOR
- PFS
- OS
- TTNT
- Safety
- HRQoL
*Not a complete list of inclusion and exclusion criteria. †Not a complete list of outcomes.
Ab, antibody; CR, complete response; DOR, duration of response; GPRC5D, G protein–coupled receptor class C group 5 member D; HRQoL, health-related quality of life; iMiD, immunomodulatory drug; mAb, monoclonal antibody; MM, multiple myeloma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PI, proteasome inhibitor; SC, subcutaneous; TTNT, time to next line of therapy; VGPR, very good partial response.